KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Total Non-Current Liabilities (2016 - 2025)

Travere Therapeutics' Total Non-Current Liabilities history spans 15 years, with the latest figure at $482.8 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 8.61% year-over-year to $482.8 million; the TTM value through Dec 2025 reached $482.8 million, down 8.61%, while the annual FY2025 figure was $482.8 million, 8.61% down from the prior year.
  • Total Non-Current Liabilities reached $482.8 million in Q4 2025 per TVTX's latest filing, up from $459.1 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $620.3 million in Q4 2022 to a low of $358.2 million in Q1 2021.
  • Average Total Non-Current Liabilities over 5 years is $514.5 million, with a median of $523.8 million recorded in 2024.
  • Peak YoY movement for Total Non-Current Liabilities: soared 65.39% in 2022, then fell 11.47% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $462.2 million in 2021, then skyrocketed by 34.2% to $620.3 million in 2022, then decreased by 6.86% to $577.8 million in 2023, then decreased by 8.57% to $528.3 million in 2024, then decreased by 8.61% to $482.8 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Total Non-Current Liabilities are $482.8 million (Q4 2025), $459.1 million (Q3 2025), and $514.7 million (Q2 2025).